
Introduction
Giant cell arteritis (GCA) is a systemic vasculitis predominantly affecting large and medium-sized arteries, especially the temporal arteries and branches of the aorta. It presents with heterogeneous clinical manifestations, ranging from cranial symptoms such as headaches and jaw claudication to extracranial vascular involvement and ischemic complications including vision loss. The clinical variability complicates early diagnosis and tailored management strategies, leading to challenges in preventing severe outcomes. A deeper understanding of the genetic architecture underlying GCA clinical heterogeneity holds promise for refining disease classification and improving patient care.
Study Background and Disease Burden
GCA is the most common systemic vasculitis in adults over 50 years old, with significant morbidity chiefly due to ischemic complications such as irreversible visual loss and stroke. The clinical course is variable, with some patients exhibiting predominantly cranial symptoms, while others have a more extracranial or systemic presentation. Current diagnostic criteria and treatment protocols are largely uniform, despite this heterogeneity. Prior research has implicated the human leukocyte antigen (HLA) region as a strong genetic risk factor, but comprehensive genomic insights into phenotype-specific genetic factors remain limited. Identifying genetic biomarkers linked to distinct clinical manifestations could enable earlier diagnosis, risk stratification, and personalized therapeutic interventions.
Study Design and Methods
This landmark genome-wide association study included 3,498 patients diagnosed with GCA and 15,550 control individuals of matched ancestry. Genome-wide genotyping data were analyzed to identify single nucleotide polymorphisms (SNPs) associated with specific GCA clinical manifestations. Logistic regression models compared genotype frequencies between patients with and without each manifestation, as well as between clinical subgroups and controls. Functional annotation, leveraging the Functional Mapping and Annotation of Genome-Wide Association Studies (FUMA GWAS) platform, facilitated gene prioritization by integrating genomic and biological data. Furthermore, latent class analysis (LCA) was employed to classify patients into genetically defined subgroups based on the presence of associated variants, seeking to reveal underlying clinical phenotypic patterns.
Key Findings
The study identified seven HLA variants distinctly associated with specific clinical features of GCA, underscoring the central role of the HLA region in disease pathogenesis and clinical heterogeneity. Additionally, seven non-HLA genetic associations were uncovered across six clinical manifestations. Notably, gene prioritization highlighted candidate genes with plausible functions in GCA pathology:
IL17A was linked to limb claudication, suggesting a role for Th17-mediated immune pathways in vascular ischemia.
IL22RA1 association with jaw claudication further implicates Th17 axis involvement in cranial ischemic symptoms.
ATP2A2, encoding a sarco/endoplasmic reticulum calcium-ATPase, was associated with extracranial disease forms, consistent with its role in vascular smooth muscle function and susceptibility to aortic aneurysms.
Latent class analysis effectively stratified patients into four genetic subgroups characterized by dominant cranial symptoms, mixed cranial-extracranial involvement, extracranial-predominant disease, and an ischemic/occlusive pattern associated with a heightened risk of severe ischemic and ocular complications. This classification aligns with known clinical phenotypes, indicating genetic underpinnings for these observed variations.
Expert Commentary
This study represents a major advance in elucidating the genetic basis of clinical heterogeneity in GCA. The distinct HLA and non-HLA variants identified not only reinforce the immunogenetic complexity of GCA but also provide mechanistic insight by linking susceptibility loci with specific immune pathways, particularly the Th17 axis implicated in vascular inflammation and ischemia. The ability to stratify patients into genetically defined classes offers a compelling framework for personalized medicine in GCA, potentially allowing early identification of patients at risk for severe ischemic complications. It also holds promise for guiding tailored immunomodulatory therapies targeting pathway-specific drivers.
Though highly informative, the study has some limitations. The cohort primarily included individuals of European ancestry, which may limit generalizability to other populations with different genetic backgrounds. Longitudinal studies correlating genetic profiles with treatment responses and long-term outcomes are needed to further translate these findings into clinical practice. Moreover, functional validation of candidate genes in vascular inflammatory models will be essential to confirm their pathogenic roles.
Conclusion and Future Perspectives
This comprehensive genome-wide analysis of GCA patients stratified by clinical phenotype advances our understanding of the genetic determinants underpinning disease heterogeneity. Identification of HLA and non-HLA variants linked to distinct manifestations provides a foundation for developing genetic biomarkers that can improve diagnostic precision and individualize patient management. The genetically defined patient subgroups revealed by latent class analysis offer a new taxonomy of GCA that mirrors clinical complexity and may guide risk-adapted therapeutic strategies. Continuing integration of genomic data with clinical and biological insights promises to transform GCA care toward precision medicine, optimizing outcomes and minimizing complications.
The application of genetic profiling in routine clinical practice could enhance early detection, especially in atypical or extracranial presentations, and inform prognostic discussions. Furthermore, delineation of immune pathways driving specific phenotypes may spur the development of novel targeted therapies, tailoring immunomodulation more effectively. Future research should prioritize diverse population cohorts, longitudinal validation, and functional characterization of genetic findings to maximize clinical impact.
Funding and Registration
The study was conducted by a multinational consortium including the Spanish GCA Group, UK GCA Consortium, and Vasculitis Clinical Research Consortium, with collaborations from multiple academic institutions and clinical centers. Details regarding funding sources and clinical trial registration were not specified in the primary publication.
References
The primary study: Borrego-Yaniz G, Fuentes-Moreno V, Ortiz-Fernández L, et al. Genetic biomarkers of clinical manifestations in giant cell arteritis define distinct patient subgroups. Ann Rheum Dis. 2026;85(11):2241-2252. PMID: 42399125.
Additional background literature on GCA pathophysiology, HLA associations, and Th17 immune mechanisms can be found in relevant rheumatology and immunology journals.


